The aggregation compound Fluticasone Propionate and Salmeterol Inhaler is a formulation that contains salmeterol xinafoate and fluticasone propionate and is utilized in the management of chronic obstructive pulmonary disease (COPD) and asthma.
The common and secondary side effects of this combination are those of its individual medicates. For example, the usage of breathed corticosteroids is related to oral candidiasis (usually famed as yeast contagion, or thrush). It is suggested to rinse and mouthwash with water after inhaling the medicine as it reduces the risk of developing a candidiasis contagion.
While the use of long acting beta-adrenoceptor agonist (LABA) and inhaled steroids are suggested in asthma guidelines for the consequent improved symptom control. Concerns have been lifted that salmeterol may enhance the small perils of asthma deaths and this extra risk is not decreased with the additional usage of inhaled steroids. Other side effects from this medicine combination may include accumulated blood pressure, an irregular heartbeat, alteration in heart rate, enhanced risk of cataracts, osteoporosis and glaucoma. The combination assists in preventing indications of wheezing, cough and inadequacy of breath.